Q-omics provides the consensus-scored CLCF1 profile across patient tissues and cancer cell-line models. CLCF1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, CLCF1 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, CLCF1 RNA expression shows 17,690 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SKCM, COAD, and THYM as cancer lineages where CLCF1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLCF1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLCF1 survival associations across molecular data types. CLCF1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLCF1 RNA expression–survival associations across cancer types. High CLCF1 expression shows unfavorable associations in LIHC, LGG, MESO, PAAD and GBM, but favorable associations in SKCM. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for CLCF1 RNA expression.
This table summarizes CLCF1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for CLCF1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLCF1 shows lower tumor expression in KICH and higher tumor expression in COAD, HNSC, KIRP, LUAD and LIHC. The COAD box plot shows higher CLCF1 RNA expression in tumor versus normal tissue (log2 FC = +1.070, t-test p < 0.001).
This table shows molecular features associated with CLCF1 in patient tissues and cancer cell lines. In patient samples, CLCF1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CLCF1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
